TABLE 1.
Patient/Tumor Characteristics
| Characteristic | Number of patients (Total=54) | % |
|---|---|---|
| Sex: | ||
| Male | 37 | 69 |
| Female | 17 | 31 |
|
Median age (years): (range) |
54 (19–77) |
|
| Tumor histology*: | ||
| Glioblastoma, IDH† wildtype | 30 | 56 |
| Glioblastoma, IDH† mutant | 2 | 4 |
| Anaplastic Astrocytoma, IDH† wildtype | 8 | 15 |
| Anaplastic oligodendroglioma, IDH† mutant, 1p/19q codeleted‡ | 3 | 6 |
| Anaplastic Ganglioglioma | 1 | 2 |
| Diffuse Astrocytoma, IDH† wildtype | 3 | 6 |
| Oligodendroglioma, IDH† mutant, 1p/19q codeleted‡ | 4 | 7 |
| Ganglioglioma | 1 | 2 |
| Pilocytic Astrocytoma | 1 | 2 |
| Meningioma | 1 | 2 |
| Tumor location: | ||
| Frontal | 19 | 35 |
| Temporal | 16 | 29 |
| Parietal | 2 | 4 |
| Occipital | 3 | 6 |
| Temporoparietal | 4 | 7 |
| Frontoparietal | 2 | 4 |
| Temporoccipital | 1 | 2 |
| Frontotemporal | 1 | 2 |
| Parietooccipital | 1 | 2 |
| Thalamus | 2 | 4 |
| Cavernous Sinus | 1 | 2 |
| Cerebellum | 1 | 2 |
| Surgery: | ||
| Gross total resection | 23 | 43 |
| Subtotal resection | 25 | 46 |
| Biopsy | 5 | 9 |
| None§ | 1 | 2 |
|
Median time from resection to pre-RT MRI (weeks): (range) |
3.9 (2–20) |
|
| Radiation therapy dose, Gy (fraction size): | ||
| 60 (2) | 41 | 76 |
| 59.4 (1.8) | 6 | 11 |
| 55.8 (1.8) | 1 | 2 |
| 54 (1.8) | 3 | 6 |
| 50.4 (1.8) | 3 | 6 |
| Systemic therapy | ||
| Temozolomide** alone | 19 | 35 |
| Temozolomide** + bevacizumab | 4 | 7 |
| Temozolomide** + bevacizumab + other chemotherapy†† | 7 | 13 |
| Temozolomide** + other clinical trial‡‡ | 9 | 17 |
| Temozolomide§§ + other chemotherapy*** | 14 | 26 |
| None | 1 | 2 |
| Additional local therapy | ||
| Tumor treating fields | 2 | 4 |
Per 2016 World Health Organization Classification of Tumors of the Central Nervous System(42)
Isocitrate Dehydrogenase
Combined loss of the short arm of chromosome 1 (“1p”) and the long arm of chromosome 19 (“19q”)
Tumor was diagnosed as meningioma without histopathology.
Temozolomide given concurrently with radiotherapy for all of these patients.
Carboplatin (n=5), CCNU (n=2), irinotecan (n=1), erlotinib (n=1), veliparib (n=1), buparsilib (n=1), ipilimumab (n=1), everolimus (n=1), cilengitide (given concurrently with radiotherapy) (n=1), dasatinib (n=1).
Oncolytic retrovirus clinical trial (n=5), tumor antigen vaccine clinical trial (n=2), dendritic cell vaccine (n=2). Patients in this category also received: CCNU (n=4), carboplatin (n=3), nilotinib (n=2), capecitabine (n=1), everolimus (n=1), palbociclib (n=1), galunisertib (n=1), irinotecan (n=1).
Temozolomide given concurrently with radiotherapy in 13 of these 14 patients.
CCNU (n=9), carboplatin (n=9), irinotecan (n=4), galunisertib (n=2), nilotinib (n=2), erlotinib (n=1), palbociclib (n=1), mipsargargin (n=1), thalidomide (n=1), etoposide (n=1), trametinib (n=1), debrafinib (n=1), rapamycin (n=1), lapatinib (n=1), vemurafenib (n=1), pemetrexed (n=1).